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Abstract
Introduction: Biomarkers to identify osteoarthritis (OA) patients at risk for disease progression are needed. As part
of a proteomic analysis of knee synovial fluid from normal and OA patients, differentially expressed proteins were
identified that could represent potential biomarkers for OA. This study aimed to use mass spectrometry assays to
identify representative peptides from several proteins in synovial fluid and peripheral blood, and assess their levels
as biomarkers of OA progression.
Methods: Multiplexed high throughput selected reaction monitoring (SRM) assays were developed to measure
tryptic peptides representative of 23 proteins in matched serum and synovial fluid samples from late OA subjects
at the time of joint replacement. Subsequently plasma samples from the baseline visit of 173 subjects in an
observational OA cohort were tested by SRM for peptides from nine of these proteins: afamin, clusterin, cartilage
oligomeric matrix protein, hepatocyte growth factor, kallistatin, insulin-like growth factor binding protein, acid labile
subunit, lubricin, lumican, and pigment epithelium-derived factor. Linear regression was used to determine the
association between the peptide biomarker level at baseline and change in joint space width (ΔJSW) from baseline
to 30 months, adjusting for age and sex.
Results: In the matched cohort, 17 proteins could be identified in synovial fluid and 16 proteins were detected
in serum. For the progression cohort, the average age was 62 and average ΔJSW over 30 months was 0.68 mm.
A high correlation between different peptides from individual proteins was observed, indicating our assays correctly
measured their target proteins. Peptides representative of clusterin, lumican and lubricin showed statistically
significant associations with joint space narrowing after adjustment for age and sex. Partial R
2 values showed
clusterin FMETVAEK and lubricin LVEVNPK peptide biomarkers explains about 2 to 3% of the variability of ΔJSW,
similar to that explained by age. A biomarker score combining normalized data for both lubricin and clusterin
peptides increased the model R
2 to 0.079.
Conclusions: Our results suggest that when combined, levels of peptides representative of clusterin and lubricin in
plasma are as predictive of OA progression as age. Replication of these findings in other prospective OA cohorts is
planned.
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Osteoarthritis (OA) is a common, debilitating disease
and knee osteoarthritis is a significant public health
problem, estimated to cost up to $185 billion per year
[1]. Currently, no effective disease-modifying OA drugs
are available. The drug development pipeline has been
limited by the heterogeneity of OA, the slowly progres-
sive nature of the disease and the fact that there can be
long periods of asymptomatic degeneration. Biomarkers
that can detect those at risk for disease progression
would be beneficial and could minimize the duration
and cost of drug discovery [2].
Most biomarkers are proteins and have classically been
quantitated with immunoassays. The cost and time
needed to develop specific, well-performing antibodies
for immunoassays is limiting [3]. Mass spectrometry has
emerged as a technology that can measure proteins in
routine clinical core laboratories [4] and has the benefit
of being able to multiplex analytes and take into account
protein variants at the amino acid level [5]. Recent stud-
ies have shown mass spectrometry-based assays can have
the excellent reproducibility that is necessary for tests in
clinical laboratories [6,7].
In a previous study, we used proteomics to identify
proteins differentially expressed in OA versus normal
synovial fluid [8]. As part of a targeted search strategy
for novel OA biomarkers, we developed mass spectrom-
etry assays to measure tryptic peptides representative of
several of these proteins, as well as other proteins from
previous discovery experiments [9]. These mass spec-
trometry assays, known as selected reaction monitoring
(SRM), use synthetic isotopically labeled peptides for
quantitation. We initially developed SRM assays for
synovial fluid [8] and subsequently refined them for
serum and plasma. The objective of this study was to
test a panel of these putative biomarkers in a prospective
OA cohort to determine whether peptide concentrations
at baseline predict radiographic progression.
Methods
Study samples
Synovial fluid and serum samples were collected from
participants with full consent and approval under Insti-
tutional Review Board (IRB) protocols from Partners
Healthcare. The study set consisted of paired synovial
fluid and serum samples from 13 patients with late-stage
OA taken at the time of joint replacement surgery, and
the samples were used to refine our SRM assays.
The progression cohort used for the study was initially
described by Mazzuca et al. [10]: 253 subjects were
followed for 30 months with serial radiographs and ques-
tionnaires. From this cohort, 30% showed radiographic
progression over the study period. From the original
cohort, 173 subjects were chosen based on the availability
of complete radiographic data and BMI <35 to exclude
outliers. The plasma used for assays was from the base-
line visit. The IRB at Partners Healthcare approved the
protocol.
SRM assays
SRM assays were developed on a TSQ Vantage triple
quadrupole mass spectrometer, (Thermo Fisher Scientific,
Waltham, MA, USA) as previously described [7,8,11-13].
No depletion of abundant proteins was required. These
assays were used to identify potential OA protein biomarkers
in paired synovial fluid and serum samples (Table 1).
To obtain quantitative data from the progression
cohort, isotopically labeled heavy peptides (AQUA,
Thermo Fisher Scientific) were spiked in each sample.
Each sample was digested and analyzed two times in the
SRM assay in duplicate for a total of four technical repli-
cates. Coefficients of variation (CVs) ranged from 3 to
15%. The average value of these replicates was used in
the analyses. Table 2 lists the 19 peptides representative
of 9 proteins in plasma used in these assays.
Thermo Scientific Pinpoint SRM Workflow software
was used for targeted protein quantification. This soft-
ware algorithm is used to predict candidate peptides and
for choosing multiple fragment ions for SRM assay
design, building an instrument method and a sequence
file, and also for automatic peptide identity confirmation
and quantitative data processing.
Knee imaging
All patients underwent standardized radiography includ-
ing semi-flexed anterior-posterior (AP) views of each
knee at the baseline and 30-month follow-up study visit
[10]. Both knees were analyzed and the knee with the
maximal joint loss during the 30-month follow up was
used as the index knee to determine the joint space
width for analyses.
Statistical analysis
We used linear regression to determine the association
between each peptide biomarker level at baseline and
maximal joint space loss (mm) in the index knee from 0
to 30 months, adjusting for age and sex. A second model
adjusting for baseline JSW and body mass index (BMI)
was also performed. We obtained R
2 and partial R
2 values
for each model to assess the amount of variance explained
by the model (R
2) and the relative contribution of the bio-
marker (partial R
2). Peptides with a marginal or stronger
association (P <0.2) with joint space loss were advanced
for further modeling. A biomarker score was developed
using a weighted average of peptides showing preliminary
evidence of association (P <0.1 or odds ratio (OR) >1.5) in
the initial analyses. First, the value for each biomarker was
standardized by subtracting the mean and dividing by its
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were added to create a biomarker score from the
weighted average, with weights equal to the parameters
from linear regression. In this way, differing scales for
each biomarker did not influence the results. Linear as-
sociations between the individual peptide biomarkers
were examined using Pearson correlation. As a second-
ary analysis we examined the association between each
peptide biomarker level at baseline and 30-month
change in the Western Ontario and McMaster Univer-
sities Arthritis Index (WOMAC). All analyses were
performed using SAS.
Results
Translation of peptide biomarkers from synovial fluid to
serum
We initially selected 23 proteins as possible biomarkers
(Table 1). These proteins were selected from discovery
proteomics experiments comparing OA and normal
synovial fluid ([8,9] and data not shown) and lists of
previously published OA biomarkers. Multiple peptides
generated by tryptic digestion were tested for each of
these 23 proteins to refine our assays. Table 1 shows
those proteins that were detectible in synovial fluid
and/or serum. Peptides representative of six proteins
could not be identified in either serum or synovial fluid
(lyosomal phospholipase (ACP2), dickkopf 1 (DKK1),
follistatin (FST), hyaluronan and proteglycan link protein
(HAPLN), group XV phospholipase A2 (PLA2G15), xaa-
Pro dipeptidase (PEPD). Peptides representative of one
protein, aggrecan (ACAN) were identified in synovial fluid
but could not be identified in serum. Most important, the
SRM assays were capable of identifying peptides from 16
proteins in both synovial fluid and serum: cartilage acidic
protein 1 (CRTAC1), clusterin (CLU), cartilage oligomeric
matrix protein (COMP), fatty acid binding protein 5
(FABP5), hepatocyte growth factor (HGF), insulin-like
growth factor-binding complex acid labile subunit
(IGFALS), kallistatin (SERPINA4), lumican (LUM), matrix
metalloproteinase (MMP3), pigment epithelium-derived
factor (PEDF), procollagen C-endopeptidase enhancer 1
(PCOLCE), protein S100-A16 (S100A16), semenogelin
(SEMG2), type 1 collagen (COL1A), type 2 collagen
(COL2A1), and type 3 collagen (COL3A1).
Table 1 Proteins tested by mass spectrometry in matched synovial fluid and serum samples
Protein Protein symbol Peptides, number Synovial fluid Serum
Aggrecan ACAN 14 Y N
Cartilage acidic protein 1 CRTAC1 10 Y Y
Clusterin CLU 8 Y Y
Cartilage oligomeric matrix protein COMP 15 Y Y
Dickkopf 1 homolog DKK1 6 N N
Fatty acid binding protein 5 FABP5 2 Y Y
Follistatin FST 11 N N
Group XV phospholipase A2 PLA2G15 8 N N
Hepatocyte growth factor HGF 1 Y Y
Hyaluronan and proteoglycan link protein HAPLN 13 N N
Insulin-like growth factor-binding complex acid labile subunit IGFALS 13 Y Y
Kallistatin SERPINA4 5 Y Y
Lumican LUM 5 Y Y
Lysosomal phospholipase ACP2 6 N N
Matrix metalloproteinase 3 MMP3 10 Y Y
Pigment epithelium derived factor PEDF 12 Y Y
Procollagen C-endopeptidase enhancer 1 PCOLCE 7 Y Y
Protein S100-A16 S100A16 1 Y Y
Semenogelin-2 SEMG2 2 Y Y
Type 1 Collagen (α1, α2) COL1A 3 Y Y
Type 2 Collagen (α1) COL2A1 1 Y Y
Type 3 Collagen (α1) COL3A1 1 Y Y
Xaa-Pro dipeptidase PEPD 14 N N
Y, yes; N, no.
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progression cohort
The progression cohort used for this study was a subset
of the cohort described by Mazzuca et al. [10]. This co-
hort was predominantly female and obese. Fifty percent
had grade-3 OA of the knee at entry into the study [10].
Our subset of subjects had an average age of 62 years
and average joint space narrowing over 30 months of
0.68 mm (Table 3). About 83% of the subjects in this cohort
had osteophytes and the WOMAC pain score averaged 4.9.
We selected 19 peptides representative of 9 proteins to
test in this cohort. Seven of these proteins were included
in the matched synovial fluid/serum study (Table 1). We
also included peptides from lubricin, given reports of el-
evated lubricin expression in the OA joint [14,15], and
afamin, which we recently showed to be increased in
OA synovial fluid [8]. The proteins and the respective
peptides tested in the progression cohort are listed in
Table 2. For seven proteins multiple peptides were
tested. For ease of identification, when referring to a par-
ticular peptide, we use the protein name followed by the
first letter of the peptide tested.
All peptides negatively correlated with joint space nar-
rowing, although this correlation did not reach statistical
significance. However, peptides for clusterin, lubricin
and lumican showed preliminary evidence of association
(Table 4). In these models, clusterin(F) and lubricin(L)
had the highest R
2 value and significance. In the adjusted
models (Table 4, even numbered models), the partial R
2
values of 0.022 for clusterin(F) and 0.033 for lubricin(L)
are similar to the partial R
2 values for age in the models,
with significant P-values of <0.05. Adding baseline JSW
and BMI to the models as additional confounders did not
change the relationship between the biomarker and ΔJSW
for any peptide. Neither baseline JSW nor BMI were statis-
tically significantly associated with JSW progression in any
of the models evaluated (Additional file 1: Table S1).
As one biomarker may not be sufficient to predict OA
progression, we developed a biomarker score using a
weighted average of clusterin(F) and lubricin(L). Using
this biomarker score further increased our model R
2 to
0.079 (Table 4, model 13). As a secondary analysis, we
looked for correlations between the different peptides
for each protein. As expected, peptides that represented
the same protein were highly correlated (Table 5, bolded
correlations). In contrast, peptides from different pro-
teins had much lower correlations.
We also looked at how our peptides predicted change
in the functional WOMAC scale. The mean change in
total WOMAC over 30 months was −1.1 (SD 16.8)
(scaled 0 to 100, with 100 being the worst). Pearson cor-
relation coefficients ranged from −0.07 (PEDF(E)) to
0.10 (IGFALS(L)). None of the peptides met the P <0.2
criterion for marginal or stronger association. IGFALS
(L) displayed the highest R
2 value of 0.0095 (P =0.2031).
Discussion
The development of clinically meaningful medical thera-
peutics for OA has not progressed for decades. Unlike,
for example, rheumatoid arthritis, in which inflammatory
markers and autoantibodies portend worse outcomes, OA
Table 2 Peptides and proteins assayed by selected
reaction monitoring
Protein Peptide sequence
Afamin FLVNLVK
Afamin LPNNVLQEK
Clusterin TLLSNLEEAK
Clusterin FMETVAEK
Cartilage oligomeric matrix protein AVAEPGIQLK
Hepatocyte growth factor ESWVLTAR
Insulin-like growth factor-binding protein
complex acid labile subunit
LAELPADALGPLQR
Insulin-like growth factor-binding protein
complex acid labile subunit
TFTPQPPGLER
Kallistatin LGFTDLFSK
Kallistatin FFSAQTNR
Lubricin LVEVNPK
Lubricin TFFFK
Lubricin C(-CH2-COOH)FESFER
Lubricin GFGGLTGQIVAALSTAK
Lumican ISNIPDEYFK
Lumican FNALQYLR
Pigment epithelium-derived factor ELLDTVTAPQK
Pigment epithelium-derived factor TVQAVLTVPK
Pigment epithelium-derived factor LSYEGEVTK
Table 3 Characteristics of 173 subjects at baseline
Characteristic Mean (SD) or number (%)
Age, years 61.8 (9.6)
Body mass index, kg/m
2 30.5 (5.1)
Sex
Female 134 (77%)
Male 39 (23%)
Race
Black 35 (25%)
White 138 (20%)
Years of knee pain 9.0 (9.6)
Years of osteoarthritis diagnosis 5.9 (6.2)
WOMAC pain 4.9 (4.1)
Osteophytes 143 (83%)
Change in joint space width at 30 months −0.68 (0.64)
WOMAC, Western Ontario and McMaster Universities Arthritis Index.
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with the relatively protracted disease course of OA, has
made drug development a major challenge. The ability to
predict disease progression with a simple blood test would
be a major advance.
Here, we have developed plasma-based, mass spectrom-
etry assays to detect peptides representative of proteins we
identified as differentially expressed in OA versus normal
synovial fluid [8]. In addition, given its importance in OA
pathophysiology [16], similar assays to quantify lubricin
peptides in plasma were also developed. The high correl-
ation between different peptides for each protein suggests
that our peptide assays are representative of the level of
the protein they were designed to measure. Levels of our
peptides were correlated with maximal change in joint
space over 30 months in a well-characterized OA progres-
sion cohort. Previously published risk factors in this cohort
include age, WOMAC function, contralateral knee OA, ip-
silateral patellofemoral OA and baseline JSW [10]. In our
adjusted models, the clusterin(F) and lubricin(L) partial R
2
values were similar to age. The finding that our biomarker
score was as predictive as age, lends validity to our ap-
proach. Although the associations were modest and only
clusterin(F) and lubricin(L) achieved statistical significance
after adjusting for age and sex, the observation that all
peptides negatively correlated with maximal change in
joint space suggests our approach may be capturing, in
peripheral blood, the ongoing pathophysiology within the
OA joint. Supporting this line of reasoning is the biologic
relevance of the two proteins (clusterin and lubricin) for
which the tryptic peptides in plasma best predicted joint
space narrowing in a combined biomarker score.
Clusterin, also known as Apolipoprotein J, is a secreted
protein that regulates apoptosis and inflammation. A few
studies have observed elevated clusterin in cartilage and
synovial fluid in early OA [17,18]. Conversely, decreased
clusterin has been observed in rheumatoid arthritis syn-
ovial tissues [19]. Clusterin has multiple functions but is
best known as a complement regulatory protein where it
binds and inactivates the membrane attack complex
(MAC) [20]. Interestingly, complement was recently re-
ported to play a role in the pathogenesis of osteoarthritis
Table 4 Linear regression models
Model
number
Model R
2 Parameter Parameter
estimate
Partial
R
2
P-value
1 0.008 Clusterin(T) −1.12 0.008 0.25
2 0.061 Clusterin(T) −1.85 0.020 0.06
Age −0.01 0.029 0.02
Sex 0.24 0.023 0.05
3 0.008 Clusterin(F) −0.92 0.008 0.25
4 0.063 Clusterin(F) −1.64 0.022 0.05
Age −0.01 0.028 0.03
Sex 0.26 0.026 0.03
5 0.018 Lubricin(L) −15.03 0.018 0.08
6 0.075 Lubricin(L) −20.96 0.033 0.01
Age −0.01 0.030 0.02
Sex 0.24 0.024 0.04
7 0.009 Lubricin(T) −7.15 0.009 0.22
8 0.059 Lubricin(T) −10.43 0.018 0.07
Age −0.01 0.030 0.02
Sex 0.21 0.019 0.07
9 0.011 Lumican(F) −4.24 0.011 0.17
10 0.047 Lumican(F) −3.15 0.006 0.31
Age −0.01 0.018 0.07
Sex 0.19 0.015 0.10
11 0.009 Lumican(I) −4.14 0.009 0.21
12 0.048 Lumican(I) −3.61 0.007 0.28
Age −0.01 0.018 0.08
Sex 0.20 0.017 0.08
13 0.079 Biomarker score
1 −0.13* 0.038 0.01
Age −0.01 0.031 0.02
Sex 0.28 0.030 0.02
1Used standardized beta estimates for Clusterin(F) and Lubricin(L) from models
4 and 6, respectively, to create a weighted sum of the two biomarkers.
*One standard deviation of change in biomarker score.
Table 5 Pearson correlation matrix for clusterin, lubricin and lumican peptides
Change in joint space width (JSW) Clusterin(F) Clusterin(T) Lubricin(L) Lubricin(T) Lumican(F) Lumican(I)
Change in JSW 1.000 −0.088 −0.088 −0.135 −0.094 −0.105 −0.096
Clusterin(F) 1.000 0.920 0.514 0.488 0.346 0.356
Clusterin(T) 1.000 0.423 0.429 0.401 0.382
Lubricin(L) 1.000 0.958 0.100 0.105
Lubricin(T) 1.000 0.123 0.114
Lumican(F) 1.000 0.858
Lumican(I) 1.000
Values in bold represent strong correlation.
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from post-traumatic OA and a demonstration that sub-
lytic concentrations of MAC could promote a catabolic
phenotype in chondrocytes [21]. The higher levels of clus-
terin in the OA joint [8] and detected in plasma here may
represent activation of a compensatory, but ultimately in-
effective, protective pathway. Indeed it has been previously
reported that glomerular masangial cells upregulate
clusterin expression in response to sub-lytic MAC and in
in vivo models of glomerular injury [22]. Whether the
upregulation of clusterin in OA synovial fluid represents a
similar response should be determined.
The other biomarker that performed well in our ana-
lyses was tryptic peptide derived from lubricin, also
known as proteoglycan 4 and encoded by the PRG4
gene. This protein is found in synovial fluid, the surface
of cartilage, tendons and menisci as well as many other
tissues. It is a very large water-soluble glycoprotein with
a known role as a joint lubricant [23]. It may also have a
role in protecting cartilage surfaces and controlling
synovial cell growth [24]. Similar to clusterin, lubricin is
upregulated in OA synovial fluid and may also represent
activation of a response to local joint injury [14]. Inter-
estingly, despite this upregulation, overexpression of
lubricin within the joint in mouse models of OA is pro-
tective, suggesting the endogenous response in OA is
insufficient [15]. Thus, lubricin is both an attractive
biomarker and potential therapy for OA.
Investigations into biomarkers of OA have been un-
derway for more than 20 years yet none are in clinical
practice [25]. Urinary C-terminal telopeptide of collagen
type II (uCTX-II) and COMP have been studied for
many years as burden of disease and prognostic bio-
markers [26-28]. A recent community-based cohort
study showed higher COMP predicting incident OA
over the next 6 years [28]. Lately, interest in this area
has increased with the identification of new candidate
biomarkers for progression. More recent additions in-
clude the alarmins S100A8/S100A9 [29], showing higher
levels in those who progressed over 2 years, adipokines,
such as leptin and resistin, which predict progressive
and incident OA respectively [30], and TNF-stimulated
gene 6 (TSG-6), which predicts radiographic progression
over 3 years [31]. Some studies suggest that panels of
biomarkers may better predict outcomes and that there
is additive value in combining multiple markers [32,33].
This study introduces an approach for protein bio-
marker development to the OA field, which allows for
rapid assay development, SRM mass spectrometry, to
identify tryptic peptides representative of target proteins.
Mass spectrometry is being increasingly used in clinical
laboratories where it has been shown to be simple,
robust, precise and less costly than traditional immuno-
assays [3,5,34,35]. Moreover, the ability to multiplex
analytes in very small volumes of samples is another
strength of this technology. The assays used for this
publication required only 25 μL of sample yet were able
to identify many different peptides. Using freely available
peptide information from online repositories [36], pep-
tides can be selected and rapidly tested in SRM assays. If
detailed biology is available about post-translational
modifications of proteins, this can be incorporated into
the design of the assays as well [37].
A strength of this work is the large number of plasma
samples analyzed from the progression cohort. Further-
more, the cohort was followed prospectively with stan-
dardized radiographs and with our SRM assays we were
able to generate quantitative and reproducible data for our
target peptides. Our study has important limitations. We
performed an index knee analysis, whereby only the knee
with the greatest change in JSW was considered. The
contralateral knee, which may or may not have had pro-
gressive OA, was not taken into account. In addition, our
analysis was not powered to predict change in WOMAC
and did not incorporate relative differences in the change
in joint space in the medial versus the lateral compart-
ments or osteophyte progression, as these data were not
available. The variability of our peptides among our sam-
ples was limited, restricting our ability to detect changes
that might be associated with joint space narrowing. In
addition, this cohort already had OA, with a majority hav-
ing at least grade-3 radiographic disease. As some of our
proteins were selected based on differences in the synovial
fluid from subjects with normal and late OA, the advanced
disease in our cohort may have made it challenging to
detect major associations between these biomarkers and
change in joint space. Likewise, few differences were noted
in the synovial fluid proteome of knee OA patients with
early and late disease [8,9], suggesting the disease process
is entrenched by the time symptoms appear. Thus, meas-
urement of our biomarkers in cohorts of patients with pre-
radiographic disease is planned to see if these peptides pre-
dict OA progression. A further weakness is that our bio-
m a r k e r sw e r eo n l ym e a s u r e da tt h eb a s e l i n et i m ep o i n t .
Thus, it is unknown whether these biomarkers change
over time, and if this change may be more predictive of
OA progression than a baseline measurement. Finally, our
data focused on knee OA, so we cannot make any general-
izations to other forms of OA based on our data.
Conclusions
In conclusion, targeted mass spectrometry assays pro-
vide a rapid means to measure novel biomarkers in
human samples. Our results suggest that when com-
bined, clusterin and lubricin peptide levels in plasma are
as predictive of OA progression as age. Replication of
these findings in prospective progression and incidence
OA cohorts is planned.
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Additional file 1: Table S1. Linear regression models adjusting for age,
sex, body mass index (BMI) and baseline joint space width (JSW).
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